5 news items
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
YMAB
1 Jun 24
statements regarding the future of the Company's business, including with respect to expansion and its goals; the Company's plans and strategies
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
YMAB
1 Jun 24
assumptions; implied and express statements regarding the future of the Company's business, including with respect to expansion and its goals
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
YMAB
26 Apr 24
and express statements regarding the future of the Company's business, including with respect to expansion and its goals; the Company's plans and strategies
Y-mAbs to Present at 2024 ASCO Annual Meeting
YMAB
25 Apr 24
the future of the Company's business, including with respect to expansion and its goals; the Company's plans and strategies, development
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
YMAB
4 Mar 24
business, including with respect to expansion and its goals; the Company's plans and strategies, development, commercialization and product distribution
- Prev
- 1
- Next